Arcus (RCUS) Q4 2025 Earnings Call Transcript
The Motley Fool
by newsfeedback@fool.com (Motley Fool Transcribing)February 25, 2026
AI-Generated Deep Dive Summary
Arcus Biosciences (RCUS) delivered strong financial results in its Q4 2025 earnings call, highlighted by a significant increase in cash reserves and promising clinical data for its lead drug casdatifan. The company reported $1 billion in cash at the end of the quarter, up from $841 million the previous quarter, driven by a successful November financing round. Revenue rose to $33 million, compared to $26 million in the prior quarter, with contributions from its collaboration with Gilead. Arcus also guided full-year 2026 revenue between $45 million and $55 million, signaling confidence in its growth trajectory.
The company emphasized the clinical progress of casdatifan, a treatment for renal cell carcinoma (RCC). Key updates included a 45% objective response rate (ORR) in a late-line setting, surpassing comparable results for belzutafan. Additionally, casdatifan demonstrated a median progression-free survival (PFS) of 15.1 months, significantly longer than belzutafan's 5.6 months. These findings underscore casdatifan's potential as a best-in-class treatment, particularly in first-line settings where primary progression rates remained low at 9% compared to belzutafan's 35%. The PEAK-1 Phase 3 trial is on track for completion by year-end, with the goal of accelerating regulatory approval and patient access.
Arcus also highlighted its strategic focus on avoiding tyrosine kinase inhibitors (TKIs) in favor of combination therapies with anti-PD-1 agents. This approach aims to expand casdatifan's market potential, with peak sales projected at $5 billion across first- and second-line RCC treatments. The company's immunology pipeline is gaining momentum, with
Verticals
financeinvesting
Originally published on The Motley Fool on 2/25/2026